***Founder Notes are published quarterly for Founding Level subscribers and additionally on an as-needed basis. If you’re a Free Reader or a TTL Subscriber, look for the next regularly scheduled issue at 9:00 AM EST on Thursday May 8.***
Dear Founders,
Sometimes there’s a stock so interesting we need to discuss it right away. In this case, it’s unfit for the Trustee Portfolio, but a perfect example of how keeping an active watchlist produces the occasional payoff.
It’s not just the upside action, that’s for people suffering from “More disease,” which we’ll diagnose and treat in tomorrow’s regular issue of TTL.
What makes this stock worth the mid-week interruption is we get to see what it looks like when an old idea crumbles and its modern replacement rips into the stratosphere almost at the exact same moment.
Here’s the backdrop that’ll explain why it roughly doubled in the last few weeks…